Full metadata record

DC Field Value Language
dc.contributor.authorNeaz, M. M.-
dc.contributor.authorPasha, F. A.-
dc.contributor.authorMuddassar, M.-
dc.contributor.authorLee, So Ha-
dc.contributor.authorSim, Taebo-
dc.contributor.authorHah, Jung-Mi-
dc.contributor.authorCho, Seung Joo-
dc.date.accessioned2024-01-20T21:36:10Z-
dc.date.available2024-01-20T21:36:10Z-
dc.date.created2021-09-03-
dc.date.issued2009-03-
dc.identifier.issn1054-2523-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/132686-
dc.description.abstractThe growth and metastasis of solid tumors are dependent on angiogenesis. The vascular endothelial growth factor (VEGF) is of particular interest since it is essential for angiogenesis. The development of novel inhibitors of VEGF receptor type 2 (VEGFR-2) is important. Quantitative structure-activity relationship (QSAR) studies were performed to understand the structural factors affecting inhibitory potency of 4-aryl-5-cyano-2-aminopyrimidines. Pharmacophore models indicate that the importance of steric and hydrogen bond acceptor groups. The best-fitted pharmacophore-based alignment was used for comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). Both CoMFA (q(2) = 0.62, r(2) = 0.87, and r(predictive)(2) = 0.7) and CoMSIA (q(2) = 0.54, r(2) = 0.86, and r(predictive)(2) = 0.61) gave reasonable results. Factors such as steric bulkiness, electrostatic effect, and hydrogen bond acceptor were found to be important for the inhibitory activity. It is suggested that negatively charged, bulky H-bond accepting groups around the piperazine nitrogen would enhance inhibition against VEGFR-2.-
dc.languageEnglish-
dc.publisherSPRINGER BIRKHAUSER-
dc.subjectMOLECULAR SIMILARITY INDEXES-
dc.subjectENDOTHELIAL GROWTH-FACTOR-
dc.subjectQUANTITATIVE STRUCTURE-
dc.subjectTYROSINE KINASE-
dc.subjectANALYSIS COMSIA-
dc.subjectCOMFA-
dc.subjectQSAR-
dc.subjectANGIOGENESIS-
dc.subjectDESCRIPTORS-
dc.subjectDERIVATIVES-
dc.titlePharmacophore based 3D-QSAR study of VEGFR-2 inhibitors-
dc.typeArticle-
dc.identifier.doi10.1007/s00044-008-9113-4-
dc.description.journalClass1-
dc.identifier.bibliographicCitationMEDICINAL CHEMISTRY RESEARCH, v.18, no.2, pp.127 - 142-
dc.citation.titleMEDICINAL CHEMISTRY RESEARCH-
dc.citation.volume18-
dc.citation.number2-
dc.citation.startPage127-
dc.citation.endPage142-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000264486600005-
dc.identifier.scopusid2-s2.0-58849147423-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusMOLECULAR SIMILARITY INDEXES-
dc.subject.keywordPlusENDOTHELIAL GROWTH-FACTOR-
dc.subject.keywordPlusQUANTITATIVE STRUCTURE-
dc.subject.keywordPlusTYROSINE KINASE-
dc.subject.keywordPlusANALYSIS COMSIA-
dc.subject.keywordPlusCOMFA-
dc.subject.keywordPlusQSAR-
dc.subject.keywordPlusANGIOGENESIS-
dc.subject.keywordPlusDESCRIPTORS-
dc.subject.keywordPlusDERIVATIVES-
dc.subject.keywordAuthorCoMFA-
dc.subject.keywordAuthorCoMSIA-
dc.subject.keywordAuthorDrug design-
dc.subject.keywordAuthorPharmacophore-
dc.subject.keywordAuthorVEGFR-
dc.subject.keywordAuthor3D-QSAR-
Appears in Collections:
KIST Article > 2009
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE